Physician profile
Randall Craig
NPI 1144280249
$1,996.22
in general payments reported to CMS, 2019-2025
22 companies · $405 in 2025
The $405 reported for 2025 was more than what 84% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $72.85 · 2021: $59.33 · 2022: $330 · 2023: $376 · 2024: $462 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $614.68 | 2021-2025 | Follistim Aq, Ganirelix Acetate, Pregnyl |
| Abbvie INC. | $229.93 | 2019-2022 | |
| Emd Serono, INC. | $182.00 | 2019-2023 | |
| Becton, Dickinson and Company | $129.83 | 2025 | Bd Onclarity |
| Gynesonics, INC. | $124.99 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Vertex Pharmaceuticals Incorporated | $120.36 | 2025 | |
| Coopersurgical, INC. | $119.88 | 2021-2023 | Stripper |
| Myriad Women'S Health, INC. | $119.63 | 2023 | |
| Viiv Healthcare Company | $105.44 | 2023 | Apretude |
| Merck Sharp & Dohme LLC | $93.79 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $50.74 | 2020-2022 | |
| Boston Scientific Corporation | $20.63 | 2019 | |
| Abbott Laboratories | $16.43 | 2023 | Freestyle Libre |
| Vertical Pharmaceuticals, LLC | $14.90 | 2019 | |
| Guerbet LLC | $14.72 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $13.74 | 2020 | |
| Covidien LP | $13.47 | 2019 | |
| Galen US INC | $11.06 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.